Trial Profile
A Placebo-controlled, Single Blind, Randomized Two Part Study Toinvestigate the Tolerability, Pharmacokinetics, and brainDopamine D3 Receptor Occupancy of Increasing Repeat Doses ofGSK618334 for up to 21 Days in Healthy Volunteers.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Sep 2023
Price :
$35
*
At a glance
- Drugs GSK 618334 (Primary)
- Indications Alcoholism; Obsessive-compulsive disorders; Substance-related disorders
- Focus Adverse reactions; Pharmacokinetics
- Sponsors GSK
- 17 Jun 2011 Actual end date (Feb 2010) added as reported by ClinicalTrials.gov.
- 17 Jun 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 29 Dec 2009 New trial record